Timelines to bring NCEs to the clinic and ultimately to market continue to accelerate, requiring CMC teams to develop robust & scalable formulations prior to FiH studies. Fit-for-purpose phase I formulation result in expensive & time-consuming reformulation efforts that slow development and often do not address delivery challenges common to low solubility & low permeability development candidates. In this fireside chat,
Rod Kertner, CCO of Serán Bioscience will discuss the challenges surrounding drug development of low solubility and low permeability candidates and provide an insight into a combination approach that can improve efficiencies.
